ACADIA Pharmaceuticals Inc. (ACAD) Position Boosted by California Public Employees Retirement System

California Public Employees Retirement System lifted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 153,200 shares of the biopharmaceutical company’s stock after acquiring an additional 2,800 shares during the quarter. California Public Employees Retirement System owned approximately 0.12% of ACADIA Pharmaceuticals worth $5,771,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. FMR LLC grew its stake in ACADIA Pharmaceuticals by 0.5% in the second quarter. FMR LLC now owns 18,306,966 shares of the biopharmaceutical company’s stock worth $510,582,000 after purchasing an additional 95,823 shares during the period. Vanguard Group Inc. grew its stake in ACADIA Pharmaceuticals by 1.8% in the second quarter. Vanguard Group Inc. now owns 7,604,605 shares of the biopharmaceutical company’s stock worth $212,093,000 after purchasing an additional 134,820 shares during the period. Janus Henderson Group PLC grew its stake in ACADIA Pharmaceuticals by 62.7% in the third quarter. Janus Henderson Group PLC now owns 5,958,548 shares of the biopharmaceutical company’s stock worth $224,459,000 after purchasing an additional 2,295,881 shares during the period. BlackRock Inc. grew its stake in ACADIA Pharmaceuticals by 2.9% in the second quarter. BlackRock Inc. now owns 5,590,706 shares of the biopharmaceutical company’s stock worth $155,925,000 after purchasing an additional 157,497 shares during the period. Finally, State Street Corp grew its stake in ACADIA Pharmaceuticals by 15.8% in the second quarter. State Street Corp now owns 3,748,468 shares of the biopharmaceutical company’s stock worth $104,551,000 after purchasing an additional 510,670 shares during the period. Institutional investors own 94.02% of the company’s stock.

Shares of ACADIA Pharmaceuticals Inc. (ACAD) opened at $28.90 on Friday. ACADIA Pharmaceuticals Inc. has a 12 month low of $25.06 and a 12 month high of $41.20. The company has a market capitalization of $3,540.00, a price-to-earnings ratio of -11.75 and a beta of 3.79.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The firm had revenue of $35.58 million for the quarter, compared to analysts’ expectations of $32.03 million. During the same period in the prior year, the firm posted ($0.61) earnings per share. The company’s quarterly revenue was up 571.3% on a year-over-year basis. analysts anticipate that ACADIA Pharmaceuticals Inc. will post -2.41 EPS for the current fiscal year.

In other news, EVP Glenn Baity sold 74,321 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $30.14, for a total value of $2,240,034.94. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Laura Brege sold 25,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $30.06, for a total value of $751,500.00. Following the sale, the director now directly owns 15,000 shares in the company, valued at $450,900. The disclosure for this sale can be found here. Corporate insiders own 22.25% of the company’s stock.

Several equities research analysts recently weighed in on ACAD shares. Jefferies Group reaffirmed a “buy” rating and issued a $47.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 12th. JPMorgan Chase & Co. set a $50.00 price target on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 5th. Leerink Swann reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, October 9th. Zacks Investment Research cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Finally, JMP Securities upped their price target on ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, October 5th. One analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $48.86.

TRADEMARK VIOLATION WARNING: “ACADIA Pharmaceuticals Inc. (ACAD) Position Boosted by California Public Employees Retirement System” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/06/acadia-pharmaceuticals-inc-acad-position-boosted-by-california-public-employees-retirement-system.html.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply